Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free PCVX Stock Alerts

Vaxcyte (PCVX) Financials

Vaxcyte logo
$53.01 +1.53 (+2.97%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$53.00 0.00 (-0.01%)
As of 05/8/2026 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Vaxcyte

Annual Income Statements for Vaxcyte

This table shows Vaxcyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -29 -50 -89 -100 -223 -402 -464 -767
Consolidated Net Income / (Loss)		 -29 -50 -89 -100 -223 -402 -464 -767
Net Income / (Loss) Continuing Operations		 -29 -50 -89 -100 -223 -402 -464 -767
Total Pre-Tax Income 		-29 -50 -89 -100 -223 -402 -464 -767
Total Operating Income		 -36 -54 -90 -104 -232 -468 -570 -924
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 54 90 104 232 468 570 924
Selling, General & Admin Expense		 5.39 8.55 16 25 40 61 93 129
Research & Development Expense		 30 46 74 78 169 332 477 794
Other Operating Expenses / (Income)		 - - - 0.00 23 75 0.00 0.00
Total Other Income / (Expense), net		 6.05 4.34 0.36 3.59 8.77 66 106 157
Interest & Investment Income		 0.90 0.63 0.24 0.35 8.36 63 110 120
Other Income / (Expense), net		 5.22 3.74 0.13 3.25 0.42 2.87 -4.38 37
Basic Earnings per Share		 ($8.12) ($13.25) ($3.02) ($1.93) ($3.44) ($4.14) ($3.80) ($5.63)
Weighted Average Basic Shares Outstanding		 3.63M 3.80M 29.55M 51.92M 64.88M 97.16M 122.00M 136.09M
Diluted Earnings per Share		 ($8.12) ($13.25) ($3.02) ($1.93) ($3.44) ($4.14) ($3.80) ($5.63)
Weighted Average Diluted Shares Outstanding		 3.63M 3.80M 29.55M 51.92M 64.88M 97.16M 122.00M 136.09M
Weighted Average Basic & Diluted Shares Outstanding		 3.63M 3.80M 29.55M 51.92M 80.03M 108.41M 128.76M 143.92M
Cash Dividends to Common per Share		 - - $0.00 $0.00 $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Vaxcyte

This table shows Vaxcyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -93 -181 -95 -129 -103 -137 -141 -167 -213 -247 -321
Consolidated Net Income / (Loss)		 -93 -181 -95 -129 -103 -137 -141 -167 -213 -247 -321
Net Income / (Loss) Continuing Operations		 -93 -181 -95 -129 -103 -137 -141 -167 -213 -247 -319
Total Pre-Tax Income 		-93 -181 -95 -129 -103 -137 -141 -167 -213 -247 -319
Total Operating Income		 -113 -197 -114 -153 -140 -162 -181 -226 -242 -274 -346
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 113 197 114 153 140 162 181 226 242 274 346
Selling, General & Admin Expense		 16 18 20 21 23 29 33 32 32 32 33
Research & Development Expense		 97 104 95 132 117 134 148 194 210 242 313
Total Other Income / (Expense), net		 20 16 19 24 37 25 40 60 30 28 27
Interest & Investment Income		 18 17 22 24 28 36 33 31 29 26 27
Basic Earnings per Share		 ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02) ($1.04) ($1.22) ($1.56) ($1.81) ($2.30)
Weighted Average Basic Shares Outstanding		 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M 135.69M 136.03M 136.20M 136.09M 139.51M
Diluted Earnings per Share		 ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02) ($1.04) ($1.22) ($1.56) ($1.81) ($2.30)
Weighted Average Diluted Shares Outstanding		 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M 135.69M 136.03M 136.20M 136.09M 139.51M
Weighted Average Basic & Diluted Shares Outstanding		 95.15M 108.41M 108.80M 111.61M 124.64M 128.76M 129.00M 129.82M 130.91M 143.92M 144.40M

Annual Cash Flow Statements for Vaxcyte

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 30 -7.11 327 -316 766 -437 -9.36 -214
Net Cash From Operating Activities		 -30 -47 -47 -121 -171 -297 -453 -656
Net Cash From Continuing Operating Activities		 -30 -47 -47 -121 -171 -297 -453 -656
Net Income / (Loss) Continuing Operations		 -29 -50 -89 -100 -223 -402 -464 -767
Consolidated Net Income / (Loss)		 -29 -50 -89 -100 -223 -402 -464 -767
Depreciation Expense		 1.04 1.23 1.41 1.80 2.83 3.16 7.00 16
Amortization Expense		 - 0.00 0.00 3.06 5.67 -28 -30 -5.97
Non-Cash Adjustments To Reconcile Net Income		 -4.76 1.96 13 2.25 35 77 16 83
Changes in Operating Assets and Liabilities, net		 2.75 -0.06 28 -28 8.91 54 18 18
Net Cash From Investing Activities		 -1.77 -1.20 -1.11 -212 75 -773 -2,006 437
Net Cash From Continuing Investing Activities		 -1.77 -1.20 -1.11 -212 75 -773 -2,006 437
Purchase of Property, Plant & Equipment		 -1.77 -1.20 -1.16 -6.56 -5.84 -16 -22 -14
Purchase of Investments		 - 0.00 0.00 -336 -103 -1,330 -3,087 -1,211
Sale and/or Maturity of Investments		 - 0.00 0.00 131 183 624 1,200 1,706
Other Investing Activities, net		 - - - 0.00 0.00 -52 -97 -43
Net Cash From Financing Activities		 62 42 375 18 862 640 2,449 2.01
Net Cash From Continuing Financing Activities		 62 42 375 18 862 640 2,449 2.01
Issuance of Common Equity		 0.12 0.12 0.41 15 862 644 2,463 13
Other Financing Activities, net		 -0.28 -1.05 0.57 3.01 -0.86 -3.88 -14 -11
Effect of Exchange Rate Changes		 - -0.34 0.09 -0.44 0.14 -6.69 0.43 2.44

Quarterly Cash Flow Statements for Vaxcyte

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 14 -148 214 -93 532 -662 -41 -40 -26 -107 87
Net Cash From Operating Activities		 -58 -129 -159 -121 -61 -111 -166 -121 -143 -225 -281
Net Cash From Continuing Operating Activities		 -58 -129 -159 -121 -61 -111 -166 -121 -143 -225 -281
Net Income / (Loss) Continuing Operations		 -93 -181 -95 -129 -103 -137 -141 -167 -213 -247 -321
Consolidated Net Income / (Loss)		 -93 -181 -95 -129 -103 -137 -141 -167 -213 -247 -321
Depreciation Expense		 0.81 0.89 1.00 1.35 1.79 2.86 2.96 2.88 3.06 7.50 2.95
Amortization Expense		 -13 -0.31 -8.90 -7.81 -3.40 -9.76 -3.00 -2.38 -0.13 -0.46 -0.21
Non-Cash Adjustments To Reconcile Net Income		 41 7.51 -34 57 26 -33 15 46 55 -33 95
Changes in Operating Assets and Liabilities, net		 6.48 44 -22 -43 18 66 -40 -1.44 12 47 -58
Net Cash From Investing Activities		 22 -14 -451 -80 -917 -557 123 78 121 115 -233
Net Cash From Continuing Investing Activities		 22 -14 -451 -80 -917 -557 123 78 121 115 -233
Purchase of Property, Plant & Equipment		 -7.34 -5.25 -5.68 -7.78 -4.95 -4.02 -5.42 -1.81 -3.82 -2.65 -2.11
Purchase of Investments		 -210 -204 -688 -351 -1,233 -815 -314 -349 -255 -293 -584
Sale and/or Maturity of Investments		 239 247 249 309 354 288 465 437 389 416 366
Other Investing Activities, net		 - -52 -6.39 -31 -33 -26 -21 -7.94 -8.22 -5.77 -13
Net Cash From Financing Activities		 49 2.74 818 110 1,515 4.91 0.76 2.52 -3.67 2.41 602
Net Cash From Continuing Financing Activities		 49 2.74 818 110 1,515 4.91 0.76 2.52 -3.67 2.41 602
Issuance of Common Equity		 49 6.61 816 108 1,513 25 6.05 9.28 0.31 3.42 611
Other Financing Activities, net		 -0.45 -3.87 1.72 2.18 2.40 -21 -5.29 -6.77 -3.98 -1.01 -9.30
Effect of Exchange Rate Changes		 1.05 -7.68 6.06 -1.41 -5.58 1.35 1.17 0.80 0.29 0.18 -0.66

Annual Balance Sheets for Vaxcyte

This table presents Vaxcyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 66 393 324 1,006 1,408 3,511 3,003
Total Current Assets		 62 389 256 943 1,096 1,788 1,627
Cash & Equivalents		 59 386 69 835 397 388 174
Short-Term Investments		 - 0.00 177 97 683 1,359 1,387
Prepaid Expenses		 2.75 2.80 10 11 16 41 66
Plant, Property, & Equipment, net		 3.39 3.27 7.95 10 80 198 257
Total Noncurrent Assets		 0.58 0.55 60 53 232 1,525 1,118
Long-Term Investments		 - 0.00 27 27 163 1,388 882
Other Noncurrent Operating Assets		 0.58 0.55 33 27 70 138 236
Total Liabilities & Shareholders' Equity		 66 393 324 1,006 1,408 3,511 3,003
Total Liabilities		 12 47 40 53 167 205 317
Total Current Liabilities		 11 47 29 41 145 140 206
Accounts Payable		 3.38 30 6.76 9.80 15 48 71
Accrued Expenses		 7.08 17 13 24 113 65 106
Current Employee Benefit Liabilities		 0.41 0.28 3.46 1.18 11 21 23
Other Current Liabilities		 0.16 0.00 5.28 5.91 7.11 5.89 6.12
Total Noncurrent Liabilities		 0.71 0.12 12 12 22 65 111
Other Noncurrent Operating Liabilities		 0.69 0.11 12 12 22 65 111
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -106 346 284 954 1,240 3,306 2,686
Total Preferred & Common Equity		 -106 346 284 954 1,240 3,306 2,686
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -106 346 284 954 1,240 3,306 2,686
Common Stock		 2.97 544 583 1,476 2,165 4,698 4,839
Retained Earnings		 -109 -199 -299 -522 -924 -1,388 -2,155
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.24 -0.36 0.18 -3.87 1.59

Quarterly Balance Sheets for Vaxcyte

This table presents Vaxcyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 412 1,008 1,503 1,496 2,091 2,087 3,560 3,378 3,305 3,172 3,348
Total Current Assets		 370 841 1,310 1,295 1,517 1,481 2,214 1,717 1,716 1,767 1,813
Cash & Equivalents		 278 380 531 545 612 519 1,050 347 307 281 261
Short-Term Investments		 84 442 756 721 875 934 1,130 1,325 1,355 1,430 1,476
Prepaid Expenses		 7.53 19 23 30 31 29 33 45 54 56 76
Plant, Property, & Equipment, net		 9.95 15 16 11 85 126 163 217 242 253 261
Total Noncurrent Assets		 32 152 176 189 489 480 1,183 1,444 1,347 1,151 1,274
Long-Term Investments		 3.98 128 154 169 413 399 1,093 1,279 1,165 959 1,004
Other Noncurrent Operating Assets		 28 24 22 21 76 81 90 165 182 192 270
Total Liabilities & Shareholders' Equity		 412 1,008 1,503 1,496 2,091 2,087 3,560 3,378 3,305 3,172 3,348
Total Liabilities		 53 63 69 93 107 101 142 178 234 279 352
Total Current Liabilities		 39 53 60 86 87 83 124 97 154 200 242
Accounts Payable		 5.49 12 16 16 22 10 18 21 31 49 63
Accrued Expenses		 24 33 34 57 55 59 84 64 106 129 165
Current Employee Benefit Liabilities		 3.45 1.88 4.42 6.93 3.09 6.46 12 5.99 11 17 7.99
Other Current Liabilities		 6.43 5.95 5.99 6.03 7.20 7.29 9.64 6.13 6.30 5.77 6.09
Total Noncurrent Liabilities		 13 11 9.23 7.78 20 18 18 81 80 79 110
Other Noncurrent Operating Liabilities		 13 11 9.23 7.78 20 18 18 81 80 79 110
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 359 945 1,433 1,403 1,984 1,986 3,418 3,200 3,071 2,893 2,996
Total Preferred & Common Equity		 359 945 1,433 1,403 1,984 1,986 3,418 3,200 3,071 2,893 2,996
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 359 945 1,433 1,403 1,984 1,986 3,418 3,200 3,071 2,893 2,996
Common Stock		 804 1,527 2,087 2,149 3,001 3,132 4,669 4,729 4,769 4,800 5,478
Retained Earnings		 -444 -583 -651 -744 -1,019 -1,148 -1,251 -1,529 -1,696 -1,908 -2,476
Accumulated Other Comprehensive Income / (Loss)		 -0.66 0.05 -2.52 -2.29 2.89 1.82 0.14 -0.32 -1.89 0.86 -6.83

Annual Metrics And Ratios for Vaxcyte

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -67.98% -79.05% -8.52% -133.73% -119.30% -21.85% -46.77%
EBIT Growth		 0.00% -66.30% -77.46% -12.25% -130.88% -100.64% -23.38% -54.44%
NOPAT Growth		 0.00% -52.40% -65.42% -15.73% -124.03% -101.52% -21.69% -62.18%
Net Income Growth		 0.00% -70.51% -77.46% -12.17% -123.31% -80.00% -15.33% -65.25%
EPS Growth		 0.00% -63.18% 77.21% 36.09% -78.24% -20.35% 8.21% -48.16%
Operating Cash Flow Growth		 0.00% -54.75% 1.10% -160.34% -40.53% -73.97% -52.51% -44.84%
Free Cash Flow Firm Growth		 0.00% 0.00% 16.67% -352.22% -18.96% -123.64% -73.66% -25.54%
Invested Capital Growth		 0.00% 0.00% -700.89% 127.09% -139.45% 43.55% 7,129.62% 41.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -8.74% -33.95% -30.09% 2.75% -10.82%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -9.90% -32.06% -31.99% 4.07% -12.63%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.14% -32.32% -30.76% 5.71% -13.81%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -8.48% -28.44% -34.31% 8.61% -16.65%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -143.57% -16.22% -23.95% 17.57% -16.32%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 7.24% -49.74% -9.03% -27.27% 3.70% -20.92%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -14.81% -45.85% 4.47% -11.23%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 188.47% 37.43% 92.28% 18.33% 9.26%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.92% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.27% 98.83% 99.74% 99.66% 96.40% 86.48% 80.83% 86.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -93.21% -44.63% -31.78% -36.12% -36.67% -20.41% -25.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,133.08% 0.00% 0.00% -334.43% -347.04%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 183.82% -26.74% -31.78% -36.12% -36.67% -20.41% -25.59%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 47.26% -25.80% -35.24% -23.44% -32.43% -14.03% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -38 -63 -73 -163 -328 -399 -647
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -41.94% -11.91% -8.34% -9.90% -6.78% -2.98% -4.31%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -17.05% -26.41% -12.06% -24.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -30 -50 -89 -100 -232 -465 -574 -886
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -49 -88 -96 -223 -490 -597 -876
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.91 4.42 3.97 4.82 3.09 2.25
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.91 4.42 3.97 4.82 3.09 2.25
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 89.90 0.00 0.00 41.31 14.81
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.09 -1.11 -1.05 -0.99 -1.00 -0.96 -0.93
Leverage Ratio		 0.00 1.22 1.15 1.14 1.08 1.10 1.08 1.09
Compound Leverage Factor		 0.00 1.20 1.14 1.13 1.04 0.95 0.87 0.94
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 297.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -197.22% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 10.35 16.87 17.22 42.82 20.21 29.26 10.01
Noncontrolling Interest Sharing Ratio		 0.00% 297.22% 40.10% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 5.58 8.30 8.93 23.26 7.54 12.75 7.91
Quick Ratio		 0.00 5.34 8.24 8.57 22.98 7.43 12.46 7.59
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -33 -27 -124 -147 -330 -572 -718
Operating Cash Flow to CapEx		 -1,718.33% -3,945.19% -4,219.73% -1,859.29% -2,920.68% -1,847.78% -2,018.22% -4,780.70%
Free Cash Flow to Firm to Interest Expense		 0.00 -821.70 -3,912.67 -17,693.86 -73,668.10 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -406.21 -1,178.63 -6,661.14 -17,341.86 -85,298.50 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -429.85 -1,208.50 -6,819.00 -18,274.57 -88,219.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -5.04 -40 11 -4.31 -2.43 171 243
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.04 -35 51 -15 1.88 174 72
Enterprise Value (EV)		 0.00 381 968 983 2,829 4,733 7,068 3,597
Market Capitalization		 280 280 1,354 1,256 3,787 5,976 10,203 6,040
Book Value per Share		 $0.00 ($28.03) $6.79 $5.38 $12.07 $13.04 $26.52 $20.51
Tangible Book Value per Share		 $0.00 ($28.03) $6.79 $5.38 $12.07 $13.04 $26.52 $20.51
Total Capital		 0.00 54 346 284 954 1,240 3,306 2,686
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -59 -386 -273 -958 -1,243 -3,135 -2,443
Capital Expenditures (CapEx)		 1.77 1.20 1.11 6.53 5.84 16 22 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.31 -44 -18 -29 -130 -99 -139
Debt-free Net Working Capital (DFNWC)		 0.00 51 342 228 902 951 1,648 1,422
Net Working Capital (NWC)		 0.00 51 342 228 902 951 1,648 1,422
Net Nonoperating Expense (NNE)		 4.61 12 27 28 61 75 65 120
Net Nonoperating Obligations (NNO)		 0.00 -59 -386 -273 -958 -1,243 -3,135 -2,443
Total Depreciation and Amortization (D&A)		 1.04 1.23 1.41 4.86 8.51 -25 -23 10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($1.93) ($3.44) ($4.14) ($3.80) ($5.63)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 56.31M 64.88M 97.16M 122.00M 136.09M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.93) ($3.44) ($4.14) ($3.80) ($5.63)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 56.31M 64.88M 97.16M 122.00M 136.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.93) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 51.92M 80.03M 108.41M 128.76M 143.92M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -38 -63 -73 -163 -328 -399 -647
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -404.17 -1,260.23 -12,779.14 -14,345.14 -115,919.50 0.00 0.00 0.00
NOPAT to Interest Expense		 -331.64 -947.68 -8,958.10 -10,367.00 -81,289.60 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -427.81 -1,290.10 -12,937.00 -15,277.86 -118,840.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -355.28 -977.55 -9,115.96 -11,299.71 -84,210.10 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Vaxcyte

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 143,920,361.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 143,920,361.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -2.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -116.26% -135.81% -65.94% -68.73% -7.74% 8.55% -39.42% -24.02% -80.10% -47.38% -97.54%
EBIT Growth		 -88.06% -132.65% -63.35% -79.91% -18.01% 12.31% -48.82% -29.59% -84.55% -57.29% -99.16%
NOPAT Growth		 -92.95% -127.18% -60.79% -75.54% -23.80% 17.55% -57.94% -47.87% -73.22% -69.13% -91.30%
Net Income Growth		 -59.99% -131.65% -57.16% -88.33% -11.29% 24.18% -48.09% -29.42% -106.38% -79.83% -127.85%
EPS Growth		 2.15% -77.67% -21.43% -57.14% 8.79% 44.26% -22.35% -10.91% -87.95% -77.45% -121.15%
Operating Cash Flow Growth		 -49.29% -97.50% -233.66% -93.48% -5.49% 13.52% -4.49% 0.19% -136.06% -101.82% -68.77%
Free Cash Flow Firm Growth		 -17.24% -207.67% -351.24% -413.30% -403.09% -105.70% -72.11% -8.16% 9.74% 8.11% 15.07%
Invested Capital Growth		 -357.52% 43.55% 1,757.18% 1,909.98% 558.57% 7,129.62% 195.97% 82.44% 53.74% 41.96% 2.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -30.79% -59.95% 36.74% -27.49% 16.48% -35.76% 3.65% -13.51% -21.31% -11.19% -29.03%
EBIT Q/Q Growth		 -31.10% -77.87% 40.92% -30.59% 14.00% -32.17% -0.15% -13.82% -22.49% -12.75% -26.70%
NOPAT Q/Q Growth		 -29.70% -74.01% 41.80% -33.64% 8.54% -15.90% -11.48% -25.13% -7.14% -13.16% -26.09%
Net Income Q/Q Growth		 -35.59% -95.11% 47.45% -35.45% 19.87% -32.93% -2.65% -18.37% -27.77% -15.82% -30.07%
EPS Q/Q Growth		 -30.00% -101.10% 53.55% -29.41% 24.55% -22.89% -1.96% -17.31% -27.87% -16.03% -27.07%
Operating Cash Flow Q/Q Growth		 8.28% -123.83% -23.53% 23.71% 49.99% -83.50% -49.26% 27.13% -18.27% -56.89% -24.82%
Free Cash Flow Firm Q/Q Growth		 -12.44% -156.16% -21.41% -46.78% -10.21% -4.74% -1.58% 7.76% 8.03% -6.63% 6.12%
Invested Capital Q/Q Growth		 -325.30% 92.28% 3,560.07% 59.34% 7.75% 18.33% 45.68% -1.78% -9.19% 9.26% 4.91%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 99.98% 100.00% 100.02% 100.00% 100.00% 100.00% 100.00% 100.43%
Interest Burden Percent		 83.36% 91.45% 81.34% 84.39% 78.61% 79.05% 81.03% 84.28% 87.91% 90.31% 92.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -34.00% -36.67% -29.83% -29.08% -21.06% -20.41% -19.66% -21.65% -20.83% -25.59% -30.55%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -531.03% -406.59% -414.24% -334.43% -365.93% -320.31% -352.03% -347.04% -304.58%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -34.00% -36.67% -29.83% -29.08% -21.06% -20.41% -19.66% -21.65% -20.83% -25.59% -30.55%
Return on Equity Simple (ROE_SIMPLE)		 -21.35% 0.00% -22.02% -25.03% -14.85% 0.00% -15.93% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -79 -138 -80 -107 -98 -114 -127 -158 -170 -192 -242
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.50% -3.92% -1.05% -1.31% -0.22% -1.08% -0.58% -0.35% -1.45% -1.95% -2.76%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.10% - - - -3.43% -3.95% -5.16% -5.86% -7.15% -8.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -111 -198 -117 -153 -131 -173 -174 -198 -242 -273 -346
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -123 -197 -125 -159 -133 -180 -174 -197 -239 -266 -343
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.41 4.82 3.28 4.14 3.73 3.09 1.52 1.37 1.62 2.25 2.79
Price to Tangible Book Value (P/TBV)		 3.41 4.82 3.28 4.14 3.73 3.09 1.52 1.37 1.62 2.25 2.79
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 54.62 47.42 65.57 41.31 7.67 5.59 9.02 14.81 22.06
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.00 -0.97 -0.96 -0.98 -0.96 -0.94 -0.93 -0.94 -0.93 -0.92
Leverage Ratio		 1.08 1.10 1.06 1.05 1.05 1.08 1.06 1.07 1.07 1.09 1.09
Compound Leverage Factor		 0.90 1.01 0.86 0.89 0.82 0.86 0.86 0.90 0.94 0.98 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 30.78 20.84 36.29 48.53 53.94 29.64 16.15 10.40 9.57 10.69 13.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.14 7.54 17.42 17.88 17.88 12.75 17.70 11.11 8.83 7.91 7.49
Quick Ratio		 14.79 7.43 17.07 17.53 17.61 12.46 17.24 10.75 8.55 7.59 7.18
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -54 -140 -169 -249 -274 -287 -292 -269 -247 -264 -248
Operating Cash Flow to CapEx		 -784.14% -2,451.66% -2,802.47% -1,560.13% -1,227.17% -2,770.48% -3,065.52% -6,690.56% -3,747.52% -8,471.44% -13,318.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -32 -2.43 84 134 145 171 249 245 222 243 255
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -25 1.88 89 142 176 174 165 111 78 72 5.56
Enterprise Value (EV)		 3,350 4,733 4,600 6,363 9,481 7,068 1,911 1,367 2,006 3,597 5,622
Market Capitalization		 4,784 5,976 6,500 8,215 12,754 10,203 4,862 4,194 4,676 6,040 8,363
Book Value per Share		 $14.95 $13.04 $17.76 $18.26 $30.62 $26.52 $24.85 $23.81 $22.28 $20.51 $20.82
Tangible Book Value per Share		 $14.95 $13.04 $17.76 $18.26 $30.62 $26.52 $24.85 $23.81 $22.28 $20.51 $20.82
Total Capital		 1,403 1,240 1,984 1,986 3,418 3,306 3,200 3,071 2,893 2,686 2,996
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,434 -1,243 -1,900 -1,852 -3,273 -3,135 -2,951 -2,827 -2,671 -2,443 -2,741
Capital Expenditures (CapEx)		 7.34 5.25 5.68 7.78 4.95 4.02 5.42 1.81 3.82 2.65 2.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -56 -130 -57 -54 -90 -99 -52 -100 -144 -139 -166
Debt-free Net Working Capital (DFNWC)		 1,210 951 1,430 1,399 2,090 1,648 1,620 1,561 1,567 1,422 1,571
Net Working Capital (NWC)		 1,210 951 1,430 1,399 2,090 1,648 1,620 1,561 1,567 1,422 1,571
Net Nonoperating Expense (NNE)		 14 43 15 22 5.18 24 14 8.22 43 55 79
Net Nonoperating Obligations (NNO)		 -1,434 -1,243 -1,900 -1,852 -3,273 -3,135 -2,951 -2,827 -2,671 -2,443 -2,741
Total Depreciation and Amortization (D&A)		 -12 0.58 -7.90 -6.46 -1.61 -6.89 -0.04 0.50 2.93 7.04 2.74
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02) ($1.04) ($1.22) ($1.56) ($1.81) ($2.30)
Adjusted Weighted Average Basic Shares Outstanding		 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M 135.69M 136.03M 136.20M 136.09M 139.51M
Adjusted Diluted Earnings per Share		 ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02) ($1.04) ($1.22) ($1.56) ($1.81) ($2.30)
Adjusted Weighted Average Diluted Shares Outstanding		 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M 135.69M 136.03M 136.20M 136.09M 139.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 95.15M 108.41M 108.80M 111.61M 124.64M 128.76M 129.00M 129.82M 130.91M 143.92M 144.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -79 -138 -80 -107 -98 -114 -127 -158 -170 -192 -242
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, investor-focused read on Vaxcyte (PCVX) based on the quarterly data provided for 2022–2025. The company remains pre-revenue, with ongoing operating expenses and cash burn, but it has attracted funding through equity financings that bolster liquidity and the balance sheet. The following points summarize the most notable trends, ordered from positives to negatives.

  • Equity financings in 2024–2025 bolstered the balance sheet and liquidity, including a large common stock issuance in Q4 2024 (about $658.996M) and a smaller issuance in Q4 2025 (about $3.415M), expanding the company’s capital runway.
  • Net financing cash flows were strongly positive across several quarters, with substantial inflows in Q3 2024 (~$1.515B) and Q4 2024 (~$656.633M), indicating ongoing external funding support for development efforts.
  • Liquidity on the balance sheet remains substantial, with roughly $1.43B in Short-Term Investments and about $281M in Cash & Equivalents as of Q3 2025, providing a sizable runway for ongoing R&D and clinical programs.
  • Total assets rose to around $3.17B by Q3 2025, reflecting liquidity and investment activity rather than revenue generation.
  • Revenue has been effectively zero for multiple quarters, underscoring the company’s pre-revenue biotech stage and reliance on external funding.
  • Net income remained materially negative, with about -$212.8M in Q3 2025 and -$246.5M in Q4 2025, highlighting ongoing annual losses.
  • Cash flow from operating activities was negative in every 2025 quarter, indicating persistent cash burn (for example, about -$224.8M from continuing operations in Q4 2025).
  • Operating expenses stay elevated, driven by R&D and SG&A (Q4 2025: R&D $242.1M and SG&A $32.2M, totaling $274.3M in operating expenses), consistent with a late-stage pre-revenue development path.
  • Earnings per share remained negative across periods, with Basic/Diluted EPS at -$1.81 in Q4 2025, -$1.56 in Q3 2025, -$1.22 in Q2 2025, and -$1.04 in Q1 2025.
05/09/26 05:54 AM ETAI Generated. May Contain Errors.

Vaxcyte Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Vaxcyte's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Vaxcyte's net income appears to be on an upward trend, with a most recent value of -$766.63 million in 2025, rising from -$29.49 million in 2018. The previous period was -$463.93 million in 2024. See Vaxcyte's forecast for analyst expectations on what's next for the company.

Vaxcyte's total operating income in 2025 was -$923.68 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $923.68 million

Over the last 7 years, Vaxcyte's total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Vaxcyte's total liabilities were at $317.21 million at the end of 2025, a 54.4% increase from 2024, and a 2,597.1% increase since 2019.

In the past 6 years, Vaxcyte's cash and equivalents has ranged from $58.98 million in 2019 to $834.66 million in 2022, and is currently $173.96 million as of their latest financial filing in 2025.

Over the last 7 years, Vaxcyte's book value per share changed from 0.00 in 2018 to 20.51 in 2025, a change of 2,051.5%.


Related Companies

Financial statements for NASDAQ:PCVX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel